659 related articles for article (PubMed ID: 34635626)
1. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
Kim KS; Hong S; Ahn HY; Park CY
Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
6. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
7. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
8. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
[TBL] [Abstract][Full Text] [Related]
10. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
[TBL] [Abstract][Full Text] [Related]
14. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study.
Yoo TK; Lee MY; Kim SH; Zheng MH; Targher G; Byrne CD; Sung KC
Nutr Metab Cardiovasc Dis; 2023 May; 33(5):947-955. PubMed ID: 36746687
[TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
[TBL] [Abstract][Full Text] [Related]
18. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
[TBL] [Abstract][Full Text] [Related]
19. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
Cheng YM; Wang CC; Kao JH
Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
[TBL] [Abstract][Full Text] [Related]
20. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]